Regeneron Pharmaceuticals Net Income Trend

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

This module enables investors to look at Regeneron Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 311.7 M, Consolidated Income of 476.6 M or Cost of Revenue of 175.6 M, but also many exotic indicators such as Interest Coverage of 77.0381, Long Term Debt to Equity of 0.196 or Calculated Tax Rate of 10.7856. This module is a perfect complement to use when analyzing Regeneron Pharmaceuticals Valuation or Volatility. It can also complement various Regeneron Pharmaceuticals Technical models. Additionally take a look at analysis of Regeneron Pharmaceuticals Correlation with competitors.

Regeneron Pharmaceuticals Net Income Marginal Breakdown

Showing smoothed Net Income of Regeneron Pharmaceuticals with missing and latest data points interpolated. Net income is one of the most important fundamental items in finance. It plays a large role in Regeneron Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Regeneron Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of [NetIncNCI] from [ConsolInc]; and before the deduction of [PrefDivIS].

2.07 B

          10 Years Trend
Slightly volatile
 Net Income 

Regeneron Pharmaceuticals Regression Statistics

Arithmetic Mean 692,108,833
Geometric Mean 430,749,010
Coefficient Of Variation 123.90
Mean Deviation 649,692,972
Median 636,056,000
Standard Deviation 857,491,388
Range 2,666,160,000
R Value 0.89
R Squared 0.79
Significance 0.00011364
Slope 211,239,636

Regeneron Pharmaceuticals Net Income Over Time

2017  1,198,511,000 
2018  2,444,400,000 
2019  2,069,999,999 

Other Fundumenentals of Regeneron Pharmaceuticals